Thanks to Greg from Minnesota for forwarding the following 2 articles concerning Acute Hepatic Encephalopathy and some possible new treatment options.
The following article represents data from 2 studies presented by the UCL Liver Failure Group to the American Association for Liver Disease (AASLD) regarding OCR-002 (L-ornithine phenylacetate) at a meeting held in Boston in November of 2009. Ocera Therapeutics, Inc. of San Diego, California holds the licensed exclusive, worldwide
rights for the development and commercialisation of OCR-002. OCR-002 has the potential to reduce ammonia, down-regulate inflammation, lower oxidative stress and reduce portal hypertension in a preclinical model of cirrhosis.
UCLB (UCL Liver Failure Group Present Two Studies at the Ame
This article presents data also from Ocera Therapeutics on AST-120 in Patients With Hepatic Encephalopathy At The European Association
For The Study Of Liver Disease held in April of 2009.
AST-120 Data for Hepatic Encephalopathy
If you have information pertinent to any one of the subjects posted on my blog, I would be more than happy to share that with all readers.
Until next time,